Skip to content
OpenCapital
Get started

Emergent Biosolutions EBS Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$5.2M+528%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
——

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Cash & equivalents$161.5M+5.7%
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×—
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%—

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's increase (decrease) in contract liabilities and current deferred income?
Emergent Biosolutions (EBS) reported increase (decrease) in contract liabilities and current deferred income of $3.2M in Q1 2026.
How has Emergent Biosolutions's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Emergent Biosolutions's increase (decrease) in contract liabilities and current deferred income increased by 1166.7% year-over-year, from -$300K to $3.2M.
What is the long-term trend for Emergent Biosolutions's increase (decrease) in contract liabilities and current deferred income?
Over 3 years (2021 to 2025), Emergent Biosolutions's increase (decrease) in contract liabilities and current deferred income has grown at a -45.3% compound annual growth rate (CAGR), from -$31.8M to $5.2M.